Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 11 of 16
May 12, 2026Gene therapy holds transformative potential for treating complex diseases, but safety concerns remain paramount. Capsida's recent silence regarding the specific brain receptor targeted in its halted trial has frustrated the field and underscores the need for transparency in investigating adverse outcomes linked to novel therapies.
May 5, 2026The development represents a significant step in combining RNA-based therapeutics with a multi-faceted approach to treating complex liver diseases. Madrigal’s strategy to integrate multiple genetic medicines could transform treatment paradigms for MASH and other metabolic liver disorders, underscoring innovation at the intersection of biotechnology and precision medicine.
May 5, 2026Johnson & Johnson’s latest therapy for IBD patients did not meet all statistical benchmarks in recent trials but continues to represent a potential advancement in the treatment landscape. This blog explores the implications of these trial results and what they mean for the future of IBD therapies.
Apr 30, 2026J. Craig Venter's contributions to the field of genomics and biotechnology have left an indelible mark on modern science. As the architect of the first human genome sequencing and a relentless innovator, his career spanned decades of revolutionary scientific developments. This article dives deep into his life, scientific impact, and the nuanced legacy that continues to influence biotech today.
Apr 29, 2026The departure of seasoned scientists and inspectors from the USDA is raising alarms in the food safety community. The implications are broad, touching everything from regulatory oversight to public health assurances. This post delves into the causes, consequences, and potential mitigations of this emerging crisis.
Apr 29, 2026The phase 3 comparison underscores the competitive landscape in obesity therapeutics, highlighting advancements in molecular targets and clinical outcomes. With obesity being a growing global health challenge, these developments are critical for expanding effective treatment options.
Apr 24, 2026Otarmeni targets hearing loss linked to mutations in the otoferlin gene, a condition affecting approximately 50 newborns annually in the United States. In addition to providing the therapy at no cost, Regeneron received a pediatric disease priority review voucher, underscoring the therapy's significance and potential impact.
Apr 23, 2026The heart, by virtue of its relentless rhythm, could be naturally protected against cancer. This new theory stems from mouse model studies and opens innovative avenues for cancer prevention research. The findings invite further exploration into how mechanical forces influence cancer biology.
Apr 22, 2026At the 2026 annual meeting of the American Association for Cancer Research (AACR), key topics included the increasing prominence of Chinese biotech companies in the arena of cancer research alongside an examination of ongoing communication issues in oncology. These discussions reflect broader trends in global biotech innovation and highlight critical barriers that impact how oncology research and treatments are conveyed among stakeholders.
Apr 21, 2026Advancements in cardiovascular risk management are underway as BioAge announces promising early results for its investigational pill that significantly mitigates inflammation, a key underlying factor in cardiovascular disease development. These findings underscore a potential new approach to reducing heart risks through modulation of inflammatory processes.
Apr 21, 2026The American Association of Cancer Researchers' 2026 meeting showcased pioneering research in CAR-T immunotherapy. This includes bold approaches to targeting smoldering multiple myeloma, with trial data offering new hope for high-risk patients by potentially preventing the onset of active disease. The session also touched upon Merck’s strategic oncology initiatives and highlighted rural health disparities.
Apr 20, 2026At the American Association of Cancer Researchers' 2026 annual meeting, significant new data was unveiled showcasing the effectiveness of Revolution Medicines’ KRAS-targeting drug. This breakthrough treatment shows potential to redefine therapeutic strategies for cancers driven by KRAS mutations, a historically challenging target in oncology.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.